KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...